Scarica l'app Stockscreener
454.38
2.82%
-13.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$467.55
Aprire:
$469.17
Volume 24 ore:
1.08M
Relative Volume:
1.04
Capitalizzazione di mercato:
$59.56B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-183.96
EPS:
-2.47
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+1.22%
1M Prestazione:
+39.69%
6M Prestazione:
+81.32%
1 anno Prestazione:
+63.84%
Intervallo 1D:
$454.20
$469.81
Intervallo di 1 settimana:
$447.10
$469.81
Portata 52W:
$205.87
$469.81
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals' Insider Sales: Compliance-Driven Moves or Subtle Signals of Strategic Shift? - AInvest
Alnylam Pharmaceuticals: Insider Selling as a Signal of Discipline, Not Distrust - AInvest
Insider Selling at Alnylam Pharmaceuticals: A Closer Look at Implications for Investors - AInvest
Alnylam EVP Garg sells $1.3 million in stock - Investing.com
Three Companies That Might Be Priced Below Their Estimated Value - simplywall.st
Insider Selling at Alnylam Pharmaceuticals: Profit-Taking or a Warning Sign? - AInvest
Alnylam Shares Surge on $730M Volume After FDA Approval Boosts Market Outlook and Analysts Raise Targets - AInvest
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionWall Street Watch & Scalable Portfolio Growth Ideas - beatles.ru
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com
Free Genetic Tests May Aid People With Rare Kidney Disease - Medscape
Insider Selling Trends in Nasdaq-Listed Companies: A Cautionary Lens on Alnylam, Boston Scientific, and CSX - AInvest
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Alnylam Pharmaceuticals Inc. Reversal Rally May Surprise Bears2025 Market Overview & Technical Buy Zone Confirmations - beatles.ru
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD - Investing.com
Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return - AInvest
Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY - simplywall.st
Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity - AInvest
Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - 富途牛牛
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com
Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest
Alnylam at Canaccord Genuity: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com
Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment - TipRanks
Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace
Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock - Yahoo Finance
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil
Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks
Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest
Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance
U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada
Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance
Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
21,676 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
29,466 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Aug 18 '25 |
Sale |
453.27 |
2,274 |
1,030,727 |
50,121 |
| Greenstreet Yvonne | Chief Executive Officer |
Aug 18 '25 |
Sale |
453.27 |
6,979 |
3,163,346 |
56,221 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
22,719 |
| BONNEY MICHAEL W | Director |
Aug 18 '25 |
Option Exercise |
70.20 |
11,250 |
789,750 |
28,054 |
| BONNEY MICHAEL W | Director |
Aug 18 '25 |
Sale |
450.00 |
11,250 |
5,062,500 |
16,804 |
1.45%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):